**template for Peer Review comments**

**Technical series on synthetic biology**

|  |  |  |  |
| --- | --- | --- | --- |
| **Contact information** | | | |
| **Surname:** | | | Coppens |
|  | | |  |
| **Given Name:** | | | Fanny |
|  | | |  |
| **Government** | | | Belgium |
| **(if applicable):** | | |  |
|  | | |  |
| **Organization:** | | | Sciensano |
|  | | |  |
| **E-mail:** | | | [Fanny.Coppens@sciensano.be](mailto:Fanny.Coppens@sciensano.be) / [hsegers@naturalsciences.be](mailto:hsegers@naturalsciences.be) |
|  | | |  |
| **Comments on the Technical Series on Synthetic Biology** | | | |
| **Page #** | **Line #** | **Comment** | |
| 22 | 1 | "DBTL" instead of "DBLT" in the title above the figure | |
| 27 | 29 | This work illustrates how *E.coli* can be engineered for the production of natural and non-natural flavonoid targets : Dunstan MS et al, (2020). Engineering Escherichia coli towards de novo production of gatekeeper (2S)-flavanones: naringenin, pinocembrin, eriodictyol and homoeriodictyol. Synthetic Biology, In Press, DOI: 10.1093/synbio/ysaa012 | |
| 29 | 2-28 | The following reference could be added : https://www.nature.com/articles/s41589-020-00697-z | |
| 34 | 39 | In the area of CAR T-cells therapy, allogeneic CAR- T cell therapy has the potential to pave the way for further breakthrough in the treatment of cancer. See Depil et al., 2020, Nature reviews Drug Discovery 19, 185-199 (2020). Research in this area could be mentioned when addressing advances in clinical therapeutics. | |
| 57 | 46 | A reference elaborating on plausible pathways for potential harm via problem formulation could be added: Connelly et al., (2021) Malaria J 20(1):170 - doi: 10.1186/s12936-021-03674-6 | |
| 59 | 10 | "breeding" instead of "breading" | |
| 167 | 44 | Link is broken, please replace it with the correct link: <https://www.biosafety.be/sites/default/files/120911_doc_synbio_sbb_final.pdf> | |

Please submit your comments to [secretariat@cbd.int](mailto:secretariat@cbd.int).